文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-11 PET/CT对前列腺癌根治性放疗计划制定的潜在影响

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.
PubMed 文献 · J Nucl Med · 2018-04-13

该研究为一项临床试验的事后分析,纳入73例未接受过局部治疗的前列腺癌患者,比较基于标准临床靶区(CTV)的根治性放疗计划对68Ga-PSMA-11 PET/CT所定义病灶的覆盖情况。结果显示,基于CTV的放疗计划覆盖了69/73例(94.5%)原发灶和20/25例(80%)盆腔淋巴结病灶;68Ga-PSMA-11 PET/CT对12/73例(16.5%,放疗野覆盖前列腺、精囊和盆腔淋巴结者)和25/66例(37%,放疗野覆盖前列腺和精囊但未覆盖盆腔淋巴结者)的根治性放疗计划有重大潜在影响。

要点

  • 基于标准CTV的放疗计划覆盖94.5%原发灶和80%盆腔淋巴结病灶。
  • 68Ga-PSMA-11 PET/CT对16.5%患者(放疗野含盆腔淋巴结)有重大计划影响。
  • 放疗野未覆盖盆腔淋巴结者中37%受68Ga-PSMA-11 PET/CT重大影响。

核心结论

  • 68Ga-PSMA-11 PET/CT对73例中12例(16.5%)的根治性放疗计划有重大影响,这些患者的放疗野覆盖前列腺、精囊和盆腔淋巴结。
  • 68Ga-PSMA-11 PET/CT对66例中25例(37%)的根治性放疗计划有重大影响,这些患者的放疗野覆盖前列腺和精囊但未覆盖盆腔淋巴结。

研究设计与样本

  • 该研究为一项新药临床试验意向治疗人群的事后分析,纳入73例未接受过局部治疗的局限性前列腺癌患者,均接受68Ga-PSMA-11 PET/CT进行初始分期。
  • 73例中,中危11例(15%)、高危33例(45%)、极高危22例(30%)、N1期7例(9.5%)。
  • 由对PET结果设盲的放射肿瘤科医生在PET/CT的CT图像上勾画临床靶区(CTV),包括前列腺、精囊和(依据放射治疗肿瘤学组共识指南)盆腔淋巴结。
  • 由核医学科医生分析68Ga-PSMA-11 PET/CT图像,未被基于CTV的计划体积覆盖的68Ga-PSMA-11阳性病灶被认为对治疗计划有重大潜在影响。

主要发现

  • 全部患者均有一个或多个68Ga-PSMA-11阳性原发前列腺病灶。
  • 73例中25例(34%)有68Ga-PSMA-11阳性盆腔淋巴结,7例(9.5%)有远处转移。
  • 淋巴结转移部位按频率递减依次为:髂外(20.5%)、髂总(13.5%)、髂内(12.5%)、闭孔(12.5%)、直肠周围(4%)、腹部(4%)、膈上(4%)、骶前(1.5%)。
  • 淋巴结病灶中位大小为6 mm(范围4-24 mm)。
  • 基于CTV的放疗计划按患者分析覆盖了73个原发病灶中的69个(94.5%)和25个盆腔淋巴结病灶中的20个(80%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standard-of-care imaging for initial staging of prostate cancer (PCa) underestimates disease burden. Prostate-specific membrane antigen (PSMA) PET/CT detects PCa metastasis with superior accuracy, having a potential impact on the planning of definitive radiation therapy (RT) for nonmetastatic PCa. Our objectives were to determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT-defined disease and to assess the potential impact of 68Ga-PSMA-11 PET/CT on definitive RT planning. Methods: This was a post hoc analysis of an intention-to-treat population of 73 patients with localized PCa without prior local therapy who underwent 68Ga-PSMA PET/CT for initial staging as part of an investigational new drug trial. Eleven of the 73 were intermediate-risk (15%), 33 were high-risk (45%), 22 were very-high-risk (30%), and 7 were N1 (9.5%). Clinical target volumes (CTVs), which included the prostate, seminal vesicles, and (in accord with the Radiation Therapy Oncology Group consensus guidelines) pelvic lymph nodes (LNs), were contoured on the CT portion of the PET/CT images by a radiation oncologist masked to the PET findings. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11-positive lesions not covered by planning volumes based on the CTVs were considered to have a major potential impact on treatment planning. Results: All patients had one or more 68Ga-PSMA-11-positive primary prostate lesions. Twenty-five (34%) and 7 (9.5%) of the 73 patients had 68Ga-PSMA-11-positive pelvic LN and distant metastases, respectively. The sites of LN metastases in decreasing order of frequency were external iliac (20.5%), common iliac (13.5%), internal iliac (12.5%) obturator (12.5%), perirectal (4%), abdominal (4%), upper diaphragm (4%), and presacral (1.5%). The median size of the LN lesions was 6 mm (range, 4-24 mm). RT planning based on the CTVs covered 69 (94.5%) of the 73 primary lesions and 20 (80%) of the 25 pelvic LN lesions, on a per-patient analysis. Conclusion:68Ga-PSMA-11 PET/CT had a major impact on intended definitive RT planning for PCa in 12 (16.5%) of the 73 patients whose RT fields covered the prostate, seminal vesicles, and pelvic LNs and in 25 (37%) of the 66 patients whose RT fields covered the prostate and seminal vesicles but not the pelvic LNs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Calais J, Kishan AU, Cao M, et al. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018. PMID: 29653978. doi:10.2967/jnumed.118.209387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。